Susquehanna International Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-22,600
| Closed | -$342K | – | 14521 |
|
|
2022
Q3 | $342K | Buy |
22,600
+10,400
| +85% | +$121K | ﹤0.01% | 9461 |
|
|
2022
Q2 | $92K | Buy |
12,200
+1,800
| +17% | +$12.7K | ﹤0.01% | 11550 |
|
|
2022
Q1 | $95K | Sell |
10,400
-56,800
| -85% | -$438K | ﹤0.01% | 11953 |
|
|
2021
Q4 | $472K | Buy |
+67,200
| New | +$703K | ﹤0.01% | 9369 |
|
|
2021
Q1 | – | Sell |
-24,100
| Closed | -$326K | – | 13059 |
|
|
2020
Q4 | $326K | Buy |
+24,100
| New | +$291K | ﹤0.01% | 9113 |
|
|
2020
Q3 | – | Sell |
-16,900
| Closed | -$249K | – | 11362 |
|
|
2020
Q2 | $249K | Buy |
16,900
+1,200
| +8% | +$17.8K | ﹤0.01% | 8666 |
|
|
2020
Q1 | $212K | Sell |
15,700
-122,600
| -89% | -$2.33M | ﹤0.01% | 8583 |
|
|
2019
Q4 | $3.34M | Buy |
138,300
+65,700
| +90% | +$1.36M | ﹤0.01% | 3530 |
|
|
2019
Q3 | $1.4M | Buy |
72,600
+10,000
| +16% | +$229K | ﹤0.01% | 4983 |
|
|
2019
Q2 | $1.85M | Sell |
62,600
-19,600
| -24% | -$755K | ﹤0.01% | 4324 |
|
|
2019
Q1 | $3.9M | Sell |
82,200
-61,000
| -43% | -$2.68M | ﹤0.01% | 2754 |
|
|
2018
Q4 | $5.17M | Buy |
143,200
+6,400
| +5% | +$300K | ﹤0.01% | 2251 |
|
|
2018
Q3 | $8.42M | Buy |
136,800
+12,200
| +10% | +$784K | ﹤0.01% | 2116 |
|
|
2018
Q2 | $8.42M | Sell |
124,600
-78,100
| -39% | -$4.37M | ﹤0.01% | 2116 |
|
|
2018
Q1 | $11M | Buy |
202,700
+32,100
| +19% | +$1.8M | ﹤0.01% | 1695 |
|
|
2017
Q4 | $10.2M | Sell |
170,600
-158,300
| -48% | -$9.6M | ﹤0.01% | 1810 |
|
|
2017
Q3 | $16M | Buy |
328,900
+206,500
| +169% | +$11.3M | 0.01% | 1399 |
|
|
2017
Q2 | $6.43M | Sell |
122,400
-1,800
| -1% | -$83.8K | ﹤0.01% | 2111 |
|
|
2017
Q1 | $5.63M | Sell |
124,200
-6,900
| -5% | -$308K | ﹤0.01% | 2236 |
|
|
2016
Q4 | $4.96M | Buy |
131,100
+9,100
| +7% | +$344K | ﹤0.01% | 2449 |
|
|
2016
Q3 | $4.6M | Sell |
122,000
-37,400
| -23% | -$825K | ﹤0.01% | 2344 |
|
|
2016
Q2 | $2.81M | Buy |
159,400
+121,400
| +319% | +$1.97M | ﹤0.01% | 3028 |
|
|
2016
Q1 | $462K | Sell |
38,000
-66,700
| -64% | -$1.06M | ﹤0.01% | 6549 |
|
|
2015
Q4 | $2.55M | Sell |
104,700
-312,900
| -75% | -$7.3M | ﹤0.01% | 3592 |
|
|
2015
Q3 | $7.41M | Buy |
417,600
+191,300
| +85% | +$3.46M | ﹤0.01% | 2169 |
|
|
2015
Q2 | $3.99M | Buy |
226,300
+204,700
| +948% | +$3.75M | ﹤0.01% | 3298 |
|
|
2015
Q1 | $677K | Buy |
+21,600
| New | +$626K | ﹤0.01% | 6555 |
|
Susquehanna International Group's AERI Position: Q4 2022 in Review
Susquehanna International Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 14,877 shares — an estimated $225K sold.
Susquehanna International Group first reported a position in AERI in Q1 2015 and held it in 22 quarters. The position peaked at $10.7M in Q4 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Susquehanna International Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Susquehanna International Group sold 14,877 Aerie Pharmaceuticals shares in Q4 2022, an estimated $225K.
- Susquehanna International Group first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 22 quarters.
- Susquehanna International Group's Aerie Pharmaceuticals position peaked at $10.7M in Q4 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.